Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dabrafenib-trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non-small-cell lung cancer.

Literature DB >> 33278771

Dabrafenib-trametinib combination therapy re-challenge in advanced BRAF^V600E-mutant non-small-cell lung cancer.

Fumihiro Kashizaki¹, Arihito Tanaka², Shigeaki Hattori³, Shunsuke Sugimoto⁴.

Abstract

Entities: Chemical Disease Mutation

Year: 2020 PMID： 33278771 DOI： 10.1016/j.ejca.2020.11.002

Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162

Keyword Cloud
Cited

× No keyword cloud information.

3 in total

Review 1. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.

Authors: Ioannis Tsamis; Georgia Gomatou; Stavroula Porfyria Chachali; Ioannis Panagiotis Trontzas; Vasileios Patriarcheas; Emmanouil Panagiotou; Elias Kotteas
Journal: Clin Transl Oncol Date: 2022-06-21 Impact factor: 3.405

2. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF ^V600E-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.

Authors: Yaran Xue; Yaqian Ren; Bing Yan; Zhaona Li; Chun Huang
Journal: Ann Transl Med Date: 2022-09

3. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.

Authors: Jingjing Qu; Qian Shen; Yuping Li; Farhin Shaheed Kalyani; Li Liu; Jianya Zhou; Jianying Zhou
Journal: Front Oncol Date: 2022-06-22 Impact factor: 5.738

3 in total

Dabrafenib-trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non-small-cell lung cancer.

Review 1. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.

2. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF V600E-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.

3. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.

Dabrafenib-trametinib combination therapy re-challenge in advanced BRAF^V600E-mutant non-small-cell lung cancer.

2. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF ^V600E-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.